Current Headlines

  1. Skyhawk Therapeutics Announces Agreement With Takeda To Develop Novel Small Molecule RNA Splicing Modifiers For Neurodegenerative Diseases

    Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR™technology platform to discover and pre-clinically develop innovative small molecule treatments directed to certain neurological disease targets

  2. Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For mRNA ISH Tissue Analysis

    Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced it has expanded its partnership with Bio-Techne by offering drug discovery researchers in the U.S. new chromogenic detection kits for automated in situ hybridization (ISH) tissue analysis

  3. WuXi AppTec Acquires Pharmapace To Enhance Biometrics Services For Clinical Development

    WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support

  4. Arcus Biosciences And Strata Oncology Announce Clinical Development Collaboration For Anti-PD-1 Antibody AB122

    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, recently announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy

  5. Presage Announces Collaboration With Celgene To Investigate Novel Agents With CIVO™ Technology

    Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ intratumoral microdosing platform, today announced it has entered into a research collaboration with Celgene Corporation to evaluate several of Celgene's early stage assets in Phase 0 trials

  6. Researchers Discover The Mechanism Of Action Of An Antitumour Drug Used For The Treatment Of Glioblastoma

    Glioblastoma is an incurable type of brain tumour that is frequently associated with mutations in the epidermal growth factor receptor (EGFR). The main EGFR mutation found in glioblastomas, called EGFRvIII, is treated with the antibody mAb806, a drug developed by the Ludwig Institute for Cancer Research (US) about 20 years ago, but whose mechanism of action was unknown

  7. Agios Announces FDA Approval Of Supplemental New Drug Application (sNDA) For TIBSOVO® As Monotherapy For Newly Diagnosed Adult Patients With IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible For Intensive Chemotherapy

    Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. Prescribing Information for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor, to include adult patients with newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

  8. CStone And Numab Announce Exclusive Regional Licensing Agreement For ND021, A Multi-Functional Drug Candidate And Potential Next-Generation Immunotherapy

    CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA)

  9. Thermo Fisher Scientific Completes Acquisition Of Brammer Bio

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.  The completion of the transaction follows the receipt of all required regulatory approvals.

  10. Invicro And iThera Medical Announce A Strategic Partnership To Enhance In Vivo Imaging Capabilities With The MSOT inVision Optoacoustic Imaging Platform

    Invicro LLC, a Konica Minolta company and iTheraMedical GmbH announced a unique partnership with the placement of the MSOT inVision platform in Invicro’s in vivo laboratory out of its Boston headquarters